CFZ533
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graves' Disease
Conditions
Graves' Disease
Trial Timeline
Apr 19, 2016 → Apr 24, 2017
NCT ID
NCT02713256About CFZ533
CFZ533 is a phase 2 stage product being developed by Novartis for Graves' Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02713256. Target conditions include Graves' Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04129528 | Phase 2 | Completed |
| NCT03905525 | Phase 2 | Completed |
| NCT02713256 | Phase 2 | Completed |
Competing Products
6 competing products in Graves' Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rilzabrutinib dose 1 + Rilzabrutinib dose 2 | Sanofi | Phase 2 | 51 |
| RVT-1401 | Immunovant | Phase 2 | 49 |
| IMVT-1402 | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |
| RVT-1401 (Administered via subcutaneous injection) | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |